Department of Gastroenterology, The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou Youdian Road No. 54, Hangzhou, 310006, China.
Rheumatol Int. 2013 Oct;33(10):2513-21. doi: 10.1007/s00296-013-2756-6. Epub 2013 Apr 19.
The ability of non-steroidal anti-inflammatory drugs (NSAIDs) to injure the small intestine has been well established in humans and animals. Proton pump inhibitors (PPIs) are frequently prescribed to reduce gastric and duodenal injury caused in high-risk patients taking NSAIDs. However, scarce information is available concerning the effects of PPIs on intestinal damage induced by NSAIDs, and the suppression of gastric acid secretion by PPIs is hard to provide any protection against the damage caused by NSAIDs in the small intestine. The present study was designed to examine the effects of intragastric treatment of two PPIs widely used in clinical practice, namely omeprazole and pantoprazole, on the intestinal damage induced by administration of diclofenac in rat. Male SD rats were treated with omeprazole or pantoprazole for 9 days, with concomitant treatment with anti-inflammatory doses of diclofenac on the final 5 days. The anatomical lesion, villous height, the thickness, and the section area of small intestine were quantitatively analyzed. The change of ultrastructural organization was observed. Endotoxin level in blood was measured by photometry. Epidermal growth factor was observed by immunohistochemistry. Omeprazole and pantoprazole didn't decrease the macroscopic and histologic damage induced by diclofenac in the rat's small intestine. In the two PPI groups, villous height was (89.6 ± 11.8 and 92.6 ± 19.3 μm) lower than which of the control group (P < 0.05). The thickness became thinning, and the section area became small. LPS levels in the portal blood of omeprazole and pantoprazole were (4.36 ± 1.26 and 4.25 ± 1.17 EU/ml), significantly higher than in controls (P < 0.05). The EFG of PPI group descended significantly compared with the control group (P < 0.05). Omeprazole and pantoprazole cannot protect the small intestine from the damage induced by diclofenac in the conscious rat. PPIs cannot repair NSAID-induced intestinal damage at least in part because of significant lesion in mechanical barrier function and reduction in epidermal growth factor.
非甾体抗炎药(NSAIDs)损伤小肠的能力在人类和动物中已经得到充分证实。质子泵抑制剂(PPIs)常用于减少高危患者服用 NSAIDs 时引起的胃和十二指肠损伤。然而,关于 PPI 对 NSAIDs 引起的肠道损伤的影响的信息很少,并且 PPI 抑制胃酸分泌很难为 NSAIDs 在小肠引起的损伤提供任何保护。本研究旨在检查两种广泛用于临床实践的 PPIs,即奥美拉唑和泮托拉唑,在给大鼠服用双氯芬酸时对肠道损伤的影响。雄性 SD 大鼠用奥美拉唑或泮托拉唑治疗 9 天,同时在最后 5 天用抗炎剂量的双氯芬酸治疗。定量分析解剖损伤、绒毛高度、小肠厚度和截面积。观察超微结构组织的变化。通过比色法测量血液中的内毒素水平。通过免疫组织化学观察表皮生长因子。奥美拉唑和泮托拉唑并不能减少双氯芬酸在大鼠小肠引起的大体和组织学损伤。在这两种 PPI 组中,绒毛高度(89.6±11.8 和 92.6±19.3μm)低于对照组(P<0.05)。厚度变薄,截面积变小。奥美拉唑和泮托拉唑门静脉血中的 LPS 水平(4.36±1.26 和 4.25±1.17 EU/ml)明显高于对照组(P<0.05)。PPI 组的 EFG 明显低于对照组(P<0.05)。奥美拉唑和泮托拉唑不能保护小肠免受双氯芬酸在清醒大鼠中引起的损伤。PPIs 不能修复 NSAID 引起的肠道损伤,至少部分原因是机械屏障功能的显著损伤和表皮生长因子的减少。